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Abstract
Importance—Valproate is used for the treatment of epilepsy and other neuropsychological 
disorders and may be the only treatment option for women of childbearing potential. However, 
prenatal exposure to valproate may increase the risk of autism.
Objective—To determine whether prenatal exposure to valproate is associated with an increased 
risk of autism in offspring.
Design, Setting, and Participants—Population-based study of all children born alive in 
Denmark from 1996 to 2006. National registers were used to identify children exposed to 
valproate during pregnancy and diagnosed with autism spectrum disorders (childhood autism 
[autistic disorder], Asperger syndrome, atypical autism, and other or unspecified pervasive 
developmental disorders). We analyzed the risks associated with all autism spectrum disorders as 
well as childhood autism. Data were analyzed by Cox regression adjusting for potential 
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confounders (maternal age at conception, paternal age at conception, parental psychiatric history, 
gestational age, birth weight, sex, congenital malformations, and parity). Children were followed 
up from birth until the day of autism spectrum disorder diagnosis, death, emigration, or December 
31, 2010, whichever came first.
Main Outcomes and Measures—Absolute risk (cumulative incidence) and the hazard ratio 
(HR) of autism spectrum disorder and childhood autism in children after exposure to valproate in 
pregnancy.
Results—Of 655 615 children born from 1996 through 2006, 5437 were identified with autism 
spectrum disorder, including 2067 with childhood autism. The mean age of the children at end of 
follow-up was 8.84 years (range, 4-14; median, 8.85). The estimated absolute risk after 14 years of 
follow-up was 1.53% (95% CI, 1.47%- 1.58%) for autism spectrum disorder and 0.48% (95% CI, 
0.46%-0.51%) for childhood autism. Overall, the 508 children exposed to valproate had an 
absolute risk of 4.42% (95% CI, 2.59%-7.46%) for autism spectrum disorder (adjusted HR, 2.9 
[95% CI, 1.7-4.9]) and an absolute risk of 2.50% (95% CI, 1.30%-4.81%) for childhood autism 
(adjusted HR, 5.2 [95% CI, 2.7-10.0]). When restricting the cohort to the 6584 children born to 
women with epilepsy, the absolute risk of autism spectrum disorder among 432 children exposed 
to valproate was 4.15% (95% CI, 2.20%-7.81%) (adjusted HR, 1.7 [95% CI, 0.9-3.2]), and the 
absolute risk of childhood autism was 2.95% (95% CI, 1.42%-6.11%) (adjusted HR, 2.9 [95% CI, 
1.4-6.0]) vs 2.44% (95% CI, 1.88%-3.16%) for autism spectrum disorder and 1.02% (95% CI, 
0.70%-1.49%) for childhood autism among 6152 children not exposed to valproate.
Conclusions and Relevance—Maternal use of valproate during pregnancy was associated 
with a significantly increased risk of autism spectrum disorder and childhood autism in the 
offspring, even after adjusting for maternal epilepsy. For women of childbearing potential who use 
antiepileptic medications, these findings must be balanced against the treatment benefits for 
women who require valproate for epilepsy control.
Antiepileptic drug exposure during pregnancy has been associated with an increased risk for 
congenital malformations and delayed cognitive development in the offspring,1-3 but little is 
known about the risk of other serious neuropsychiatric disorders. Autistic symptoms have 
been described in case series of children exposed in utero to valproic acid,4-7 and it has been 
suggested that valproate given to animals during pregnancy may constitute an experimental 
model of autism.8-10
Genes play a significant role in the risk of autism, and disease-related genes may be 
identified in up to 25% of children with autism.11 However, a variety of environmental 
factors may increase the risk of autism,12 and prenatal valproate exposure would be a 
modifiable environmental exposure.
Autism spectrum disorders are characterized by social and communication difficulties and 
by stereotyped or repetitive behaviors and interests.13 The autism spectrum disorders include 
childhood autism (autistic disorder), Asperger syndrome, atypical autism, and other or 
unspecified pervasive developmental disorders. We analyzed the risks associated with all 
autism spectrum disorders and with the most severe of the autism spectrum disorders, 
childhood autism. A diagnosis of childhood autism requires symptoms related to (1) 
stereotyped patterns of behavior, (2) impaired social interaction, and (3) impaired 
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communication. Symptoms in at least 1 area must manifest before age 3 years. In this large 
population-based cohort study, we evaluated the association between maternal use of 
valproate during pregnancy and the risk of autism spectrum disorder and childhood autism 
in the offspring, taking parental history of epilepsy and psychiatric conditions into account.
METHODS
We conducted a population-based cohort study on the risk of autism in children exposed 
prenatally to valproate. The risk estimates were adjusted for known risk factors for autism. 
We also estimated the effects of valproate dose, trimester of exposure, valproate 
polytherapy, congenital malformations, and maternal history of epilepsy.
Ethical Approval
All data were analyzed at Statistics Denmark using encrypted identification numbers with no 
contact with the individuals. The study was approved by the Danish Data Protection Agency 
and a Danish Regional Ethical Committee. The requirement for informed consent was 
waived because of the use of deidentified data.
Study Population
We identified all children born alive in Denmark between January 1, 1996, and December 
31, 2006, using data from the Danish Civil Registration System.14 The unique personal 
identification number includes information on sex and age and was used to ensure complete 
linkage of individual information in all national registries used in this study.
Medication Exposure
The Danish Prescription Register holds information on all prescriptions filled since January 
1, 1996. Information about medical treatment given only in hospitals is not part of the 
register. It is not possible to purchase antiepileptic drugs in Denmark without a prescription. 
We defined the exposure window from 30 days before the estimated day of conception to 
the day of birth and included children with an estimated time of conception after February 1, 
1996, who were born up until December 31, 2006. Exposure for antiepileptic medication 
was defined as any filled prescription with Anatomical Therapeutic Classification codes 
N03A (antiepileptic drugs) and N05BA09 (clobazam).
Children were defined as having been exposed to monotherapy if their mothers had filled 
prescriptions for only 1 type of antiepileptic drug and as exposed to polytherapy if their 
mothers had filled prescriptions for more than 1 type of antiepileptic drug. For both 
monotherapy and polytherapy, the mothers may have filled prescriptions for other types of 
medicine. We also estimated the risk of autism spectrum disorder and childhood autism 
among the offspring of users of frequently used antiepileptic drugs other than valproate 
(carbamazepine, clonazepam, lamotrigine, and oxcarbazepine).
The estimated mean daily dose of antiepileptic drugs was calculated from the total amount 
of antiepileptic drug filled during the time from 30 days before pregnancy to birth divided 
by the number of days in the same period. The defined daily dose (DDD)36 is the assumed 
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average maintenance dose per day for a drug used for its main indication in adults. Based on 
the DDD, the estimated daily antiepileptic drug dose was dichotomized into high (>50% of 
DDD) and low (≤50% of DDD).
Diagnostic and Covariate Information
The Danish Psychiatric Central Register was used to identify children diagnosed for the first 
time with autism spectrum disorder (International Statistical Classification of Diseases, 
Tenth Revision [ICD-10] codes F84.0, F84.1, F84.5, F84.8, and F84.9]) and with childhood 
autism (ICD-10 code F84.0). The same register was used to identify parents diagnosed with 
psychiatric disorders before birth of the child (International Statistical Classification of 
Diseases, Eighth Revision [ICD-8] codes 290-315 and ICD-10 codes F0.00-F99.9). 
Gestational age, birth weight, and parity information were obtained from the Danish Birth 
Register. We used the National Hospital Register to identify children diagnosed with 
congenital malformations (ICD-10 codes Q0 to Q99 [except for Q53, undescended testicle, 
and Q65, congenital deformities of hip, because of low validity of these diagnoses])15 and 
also to identify parents diagnosed with epilepsy before birth of the child (ICD-8 code 345 
and ICD-10 codes G40 and G41).
Analytical Strategy
Children were followed up from birth to death, emigration, diagnosis of autism spectrum 
disorder or childhood autism, or December 31, 2010, whichever came first. Risk and 
prevalence estimates were reported with 95% CIs. P < .05 was used to define significance, 
using 2-sided testing.
The primary outcome was the hazard ratio (HR) of autism spectrum disorder and childhood 
autism after valproate exposure in pregnancy. We used Cox regression to estimate the HR 
for autism spectrum disorder, with age of the child as the underlying time scale and with 
separate baseline diagnostic rates (strata) for each birth year group to adjust for the 
increasing prevalence of autism spectrum disorder. The proportional hazards assumption 
was evaluated for all variables by comparing estimated log-minus-log survivor curves over 
the different categories of variables investigated. Control for the lack of independence of 
children within the same family was obtained using a robust (Huber-White) variance 
estimator. We adjusted for differences in both length of follow-up and autism spectrum 
disorder prevalence time trends. Importantly, the HR did not depend on age of the child; 
thus, age is not expected to bias the HR when the children are followed up into adulthood. 
Hazard ratios were adjusted for risk factors for autism (parental age at conception, parental 
psychiatric history, gestational age, birth weight, sex of the child, congenital malformations, 
and parity).
For the primary outcome we also estimated the cumulative incidence (absolute risk) of 
autism spectrum disorder and childhood autism in unexposed children using the Kaplan-
Meier method and multiplied this estimate with the adjusted HR for the exposed children to 
estimate the absolute risk in exposed children. The absolute risk for the exposed children is 
valid under the proportional hazards assumption, because autism spectrum disorder is 
relatively rare (prevalence <10%).16
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The secondary outcome was the risk of autism following valproate exposure after stratifying 
for maternal epilepsy prior to birth.
Stratified and Sensitivity Analyses
In a sensitivity analysis to assess possible confounding by indication, we compared the 
association between autism spectrum disorder and childhood autism in offspring of women 
who used valproate during pregnancy and women who were previous users of valproate but 
who stopped at least 30 days before the estimated day of conception. This analysis addresses 
whether the illness leading to valproate use, rather than valproate exposure, was associated 
with autism in the child. We also estimated the risk of autism after stratifying the risk 
according to dose, trimester of exposure (first vs later), and use of other antiepileptic drugs 
and polytherapy and after excluding children with congenital malformations. Because 
autism is more frequent in males, we calculated the sex ratio of exposed children adjusted 
for time to diagnosis of autism spectrum disorder and compared this sex ratio with that of 
unexposed children.
Data analyses were performed using Stata version 12 (StataCorp).
RESULTS
We identified children with an estimated time of conception after February 1, 1996, who 
were born up to December 31, 2006 (N=668 468). We excluded children with likely errors 
in gestational age (≤23 weeks or ≥45 weeks) (1489 [0.2%]), those with missing values for 
gestational age (6275 [0.9%]), those with missing information about the mother (5 
[0.001%]), adopted children (3461 [0.5%]), and those who died during the first year of life 
(1623 [0.2%]). Children who died more than 1 year after birth (40 [0.01%]) and those who 
emigrated (14 492 [2.2%]) were included in the analyses and censored at time of death or 
emigration. After exclusion, the study cohort comprised 655 615 children born to 428 407 
mothers, including multiple births of 26 418 children (4.0%).
The mean age of the children at end of follow-up was 8.84 years (range, 4-14; median, 
8.85). During the study period, 5437 children were diagnosed with autism spectrum 
disorder, including 2067 with childhood autism. Characteristics of the study participants are 
shown in Table 1.
We identified 2644 children exposed to antiepileptic drugs during pregnancy, including 508 
exposed to valproate. The overall use of antiepileptic drugs during pregnancy remained 
stable during the study period; however, valproate use decreased and lamotrigine use 
increased (Figure 1) (eTable 1, available at http://www.jama.com). The median number of 
valproate prescriptions filled during pregnancy was 4 (range, 1-15), and the median time 
between 2 successive filled valproate prescriptions during pregnancy was 6 weeks (range, 
0-38).
The absolute risk after 14 years of follow-up was 1.53% (95% CI, 1.47%-1.58%) for autism 
spectrum disorder and 0.48% (95% CI, 0.46%-0.51%) for childhood autism.
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Use of valproate during pregnancy was associated with an absolute risk of 4.42% (95% CI, 
2.59%-7.46%) for autism spectrum disorder (adjusted HR, 2.9 [95% CI, 1.7-4.9]) and an 
absolute risk of 2.50% (95% CI, 1.30%- 4.81%) for childhood autism (adjusted HR, 5.2 
[95% CI, 2.7-10.0]) (Table 2). We also found higher risks of autism spectrum disorder 
(adjusted HR, 2.2 [95% CI, 1.02-4.9]) and childhood autism (adjusted HR, 5.6 [95% CI, 
1.7-18.1]) among children of women who used valproate during pregnancy compared with 
children of women who were previous users of valproate but who stopped at least 30 days 
before conception (eTable 2).
When restricting the analyses to offspring of women with epilepsy, the absolute risk of 
autism spectrum disorder in 432 children exposed to valproate was 4.15% (95% CI, 
2.20%-7.81%) (adjusted HR, 1.7 [95% CI, 0.9-3.2]) and the absolute risk for childhood 
autism was 2.95% (95% CI, 1.42%-6.11%) (adjusted HR, 2.9 [95% CI, 1.4-6.0]), when 
compared with the absolute risk of 2.44% (95% CI, 1.88%-3.16%) for autism spectrum 
disorder and 1.02% (95% CI, 0.70%-1.49%) for childhood autism among 6152 children not 
exposed to valproate (Table 3).
There was also an increased risk among exposed children of mothers without a history of 
epilepsy when compared with those unexposed to valproate, but the number of exposed 
cases of mothers without epilepsy was low (Table 3).
In a sensitivity analysis, we changed the valproate exposure window prior to pregnancy. 
Compared with unexposed women, the adjusted HRs for autism spectrum disorder were 2.3 
(95% CI, 1.4-3.9) for the window from 180 days prior to pregnancy, 2.7 (95% CI, 1.6-4.6) 
for the window from 90 days prior to pregnancy, and 3.0 (95% CI, 1.8-5.2) for the window 
from 0 days prior to pregnancy; the corresponding adjusted HRs for childhood autism were 
4.1 (95% CI, 2.1-8.0), 4.8 (95% CI, 2.5- 9.3), and 5.4 (95% CI, 2.8-10.5), respectively.
The risk of autism spectrum disorder and childhood autism was increased among 441 
valproate-exposed children whose mothers filled valproate prescriptions in the first trimester 
(adjusted HR, 2.9 [95% CI, 1.6-5.1] for autism spectrum disorder and 4.7 [95% CI, 2.2-9.9] 
for childhood autism). The adjusted HRs among 67 children whose mothers only filled 
valproate prescriptions later in pregnancy were 3.1 (95% CI, 0.8-12.2) for autism spectrum 
disorder and 8.3 (95% CI, 2.1-32.4) for childhood autism (eTable 3).
When compared with offspring not exposed to valproate, the adjusted HR of autism 
spectrum disorder among 388 children exposed to valproate monotherapy was 3.0 (95% CI, 
1.7-5.4) and the adjusted HR of childhood autism was 4.9 (95% CI, 2.3-10.3). Among 120 
children exposed to valproate polytherapy, the adjusted HR of autism spectrum disorder was 
1.9 (95% CI, 0.5- 7.7) and the adjusted HR of childhood autism was 5.2 (95% CI, 1.3-21.3) 
(eTable 4).
Risks were similar for 183 children of women who used a high valproate dose (>750 mg/d) 
(adjusted HR, 2.5 [95% CI, 1.03-6.1] for autism spectrum disorder and 4.3 [95% CI, 1.4- 
13.4] for childhood autism) compared with those for 325 children of women who used a low 
valproate dose (≤750 mg/d) (adjusted HR, 3.2 [95% CI, 1.7-6.2] for autism spectrum 
disorder and 5.4 [95% CI, 2.4-12.1] for childhood autism) (eTable 5).
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For other antiepileptic drugs, there was no increased risk of autism spectrum disorder or 
childhood autism among the offspring of women who used oxcarbazepine as monotherapy 
during pregnancy (Figure 2 and eTable 4). There were few (<5) exposed cases when 
stratifying the individual drugs by dose, especially when analyzing the risk of childhood 
autism (eTables 4 and 5).
After excluding the 25 619 children with congenital malformations from the analyses (Table 
1), the adjusted HRs associated with valproate exposure (n=457), compared with those 
associated with nonexposure (n=629 539), were 2.8 (95% CI, 1.5-5.1) for autism spectrum 
disorder and 4.2 (95% CI, 1.9- 9.3) for childhood autism (eTable 6).
The sex ratio (boys to girls; adjusted for time to event) of autism spectrum disorder was 2.4 
(95% CI, 0.8-7.7) (10 boys and 4 girls) for children exposed to valproate and 4.4 (95% CI, 
4.1-4.7) (4449 boys and 974 girls) for children not exposed to valproate (P=.32 by χ2 test). 
The sex ratio of childhood autism was 1.2 (95% CI, 0.3- 4.4) (5 boys and 4 girls) for 
children exposed to valproate and 4.6 (95% CI, 4.1-5.1) (1704 boys and 354 girls) for 
children not exposed to valproate (P=.04 by χ2 test).
DISCUSSION
In this population-based cohort study, children of women who used valproate during 
pregnancy had a higher risk of autism spectrum disorder and childhood autism compared 
with children of women who did not use valproate. Their risks were also higher than those 
for children of women who were previous users of valproate but who stopped before their 
pregnancy. Our results are consistent with findings from previous case series, although the 
risk of autism spectrum disorder following valproate exposure in our study was slightly 
lower,4-6 probably because our findings were based on a larger and unselected cohort of 
valproate-exposed women. Because autism spectrum disorders are serious conditions with 
lifelong implications for affected children and their families, even a moderate increase in 
risk may have major health importance. Still, the absolute risk of autism spectrum disorder 
was less than 5%, which is important to take into account when counseling women about the 
use of valproate in pregnancy.
Valproate is indicated for the treatment of epilepsy, manic episodes associated with bipolar 
disorder, and prophylaxis of migraine headaches. It was not possible from the prescriptions 
to identify the disorder for which the women received valproate treatment. However, we 
assume that women who had a diagnosis of epilepsy received valproate for this indication. 
An increased risk from valproate use was found in the offspring of mothers both with and 
without an epilepsy diagnosis, suggesting a biological effect of valproate. In the offspring of 
women with epilepsy, the risk associated with valproate use was lower compared with the 
overall risk from valproate. This suggests confounding effects of maternal epilepsy or 
interaction between genetic susceptibility and valproate. We cannot exclude the possibility 
that children of women who used valproate during pregnancy may be examined more 
carefully for autism spectrum disorders, because valproate has been associated with adverse 
effects.4-6 This potential bias would lead to overestimation of the effect of valproate on the 
risk of autism in our study.
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Risk of Autism According to the Timing of Exposure to Valproate
We found no difference in risk of autism spectrum disorder between offspring of women 
who redeemed prescriptions for valproate early vs later in pregnancy, but the number of 
women who redeemed valproate only in the later stages of pregnancy was low. The 
estimates were based on the trimester when the women redeemed a prescription and not on 
when the women actually ingested the tablets; therefore, misclassification of timing of the 
exposure may have occurred. Changing the exposure window prior to pregnancy had only 
minor influence on the association between valproate exposure and autism spectrum 
disorder. Misclassification of the timing of conception is also possible, but this 
misclassification is likely small.17,18
Risk of Autism by Antiepileptic Treatment Regimen
We found increased risks of autism spectrum disorder, both in offspring of women who 
filled prescriptions for valproate alone and offspring of those who filled prescriptions for 
valproate as well as other antiepileptic drugs during pregnancy; however, the number of 
women exposed to valproate polytherapy was low. We assume that women using valproate 
monotherapy did not change antiepileptic medication during pregnancy, but use of 
polytherapy may reflect a change.
Previous studies suggest that the teratogenic potential of valproate19 is higher for high daily 
doses of valproate during pregnancy.20 We found increased risks associated with both a high 
dose and a low dose. However, we did not have information on the actual dose of valproate 
or on whether the dose was changed during pregnancy, which may limit the validity of the 
analyses.
Exposures to carbamazepine, oxcarbazepine, lamotrigine, and clonazepam monotherapy 
were not associated with increased risks of autism spectrum disorder and childhood autism. 
Valproate is a fatty acid derivative and chemically different from the other antiepileptic 
drugs studied, which may explain the different results observed with different antiepileptic 
drugs.
Women who use valproate in pregnancy may use other types of drugs having a potential 
effect on the development of the nervous system. However, we did not adjust for use of 
other prescription medicines in pregnancy, because there is no consensus on what kinds of 
medicines may be associated with an increased risk of autism in the offspring.
Brain Development, Congenital Malformations, and Autism
The potential harmful effects of valproate on the developing brain give rise to health 
concerns.1,2 Several animal studies describe autistic-like behavior in offspring of mothers 
exposed to valproate during pregnancy. In animal studies, some manifestations of autism 
were reproduced by administering valproate at various stages in pregnancy, eg, increased 
repetitive or stereotypic activity, higher anxiety, and decreased level of social interaction.9,21 
The precisemode of action of valproate is not established, but it may alter neurotransmitter 
functioning involved in cell migration and differentiation, neuronal apoptosis,22 or synaptic 
plasticity23 or act via other mechanisms including attenuation of folic acid metabolism, 
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inhibition of histone deacetylases, oxidative stress, and production of arene oxide 
intermediates.24,25
Like other studies,19,20 ours found an increased risk of congenital malformations in children 
exposed to valproate, but the risk of autism spectrum disorder and childhood autism 
associated with valproate exposure persisted after restricting the analysis to children without 
congenital malformations.
Strengths and Weaknesses of the Data
We assessed a population-based cohort of all children born between 1996 and 2006 for up to 
14 years and with less than 3% loss to follow-up, making selection bias an unlikely 
explanation for our results.4-6
We assumed that most women who filled a prescription for valproate also used 
themedication at least to some extent. A previous study showed high agreement between 
maternal report of antiepileptic medication use and filled prescriptions for antiepileptic 
drugs as registered by the Danish Prescription Register.26
We did not have information on the use of antiepileptic drugs by pregnant women while 
admitted to hospitals, and we therefore may not have included all valproate-exposed 
pregnancies. However, valproate is rarely given alone for shorter intervals such as hospital 
admissions, and failure to include valproate-exposed children in our exposed cohort would 
tend to underestimate an association with prenatal valproate exposure.
We did not adjust for multiple comparisons but specified a priori that the main outcome was 
the risk of autism spectrum disorder and childhood autism following prenatal exposure to 
valproate. Multiple comparisons increase the risk of incidental findings, and the results of 
the secondary analyses are therefore exploratory and subject to further studies.
The positive predictive value of an epilepsy diagnosis in the Danish Hospital Register was 
81%27; therefore, some patients registered with epilepsy in our cohort do not have epilepsy. 
Also, patients registered with epilepsy in childhood and early adulthood may no longer have 
epilepsy. However, the associations between valproate exposure and autism spectrum 
disorders were found among offspring of mothers both with and without epilepsy, indicating 
an association with valproate exposure. Seizures may influence the well-being of the unborn 
child, but from the registers it was not possible to identify pregnant women experiencing 
seizures during pregnancy. We are not aware of studies that have assessed the contribution 
of seizures in pregnancy to the risk of autism in the offspring of women with epilepsy.
When evaluating the quality of the childhood autism diagnosis in the Danish Psychiatric 
Central Register, it was found that 94% of the childhood autism diagnoses met the ICD-10 
criteria for a correct diagnosis.28 The other autism spectrum disorder diagnoses in the 
register have not been validated, but the quality is expected to be high. In this study, the 
prevalence estimate of autism spectrum disorder was 1.53% (95% CI, 1.47%-1.58%) at 14 
years of follow-up, similar to the prevalence of 1.1% in US children aged 3 to 17 years 
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based on parent reports29 or of approximately 1% among 8-year-old US children based on 
data from the Autism and Developmental Disabilities Monitoring Network.30
We adjusted for parental psychiatric history, which is a well-known risk factor for autism in 
the offspring,31 but the estimates of the risk associated with valproate exposure changed 
little. We did not have information on use of alcohol in pregnancy, but we adjusted for 
diagnoses of alcohol abuse from the Danish Psychiatric Central Register. However, not all 
parents with alcohol abuse or psychiatric disorders were identified from the registers, and 
residual confounding by unmeasured psychiatric disorders in the mother or father can 
therefore not be entirely excluded. We did not have information on folic acid use in pregnant 
women (only high-dose [5 mg] folic acid requires a prescription in Denmark). Studies of 
folate status during the later stages of pregnancy did not find significant associations with 
mental and psychomotor development at age 5 years,32 but periconceptional use of folic acid 
has been associated with a 39% reduced risk of autistic disorder (childhood autism) 
(adjusted odds ratio for autistic disorder in children of folic acid users, 0.61 [95% CI, 
0.41-0.90]),33 and use of folic acid may reduce the risk of autism spectrum disorder in 
mothers with inefficient folate metabolism.34 However, we expect that pregnant women 
exposed to valproate would be more likely to take folic acid compared with those not 
exposed to valproate during pregnancy because of recommendations regarding the use of 
folic acid in fertile women with epilepsy, which would tend to underestimate the true risk 
associated with valproate.
CONCLUSIONS
Maternal use of valproate during pregnancy was associated with a significantly increased 
risk of autism in the offspring, even after adjusting for parental psychiatric disease and 
epilepsy. For women of childbearing potential who use antiepileptic medications, these 
findings must be balanced against the treatment benefits for women who require valproate 
for epilepsy control.
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Proportion of Women Who Filled at Least 1 Prescription for Antiepileptic Drugs During 
Pregnancy, by Birth Year of the Child See eTable 1 for number of live births, congenital 
malformations, autism spectrum disorder, chilhood autism, and antiepileptic use by the 
mother during pregnancy.
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Autism Spectrum Disorder and Childhood Autism in Offspring of Mothers Who Used 
Antiepileptic Drugs as Monotherapy During Pregnancy Compared With Offspring of 
Women Who Did Not Use the Individual Antiepileptic Drug
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Table 1
Characteristics of Study Participants
Characteristic
Valproate Exposure, No. (%)
Exposed (n = 508) Not Exposed (n = 655 107)
Maternal age at conception, y
 <21 30 (5.9) 26 212 (4.0)
 21-25 117 (23.0) 127 230 (19.4)
 26-30 190 (37.4) 262 707 (40.1)
 31-35 129 (25.4) 180 973 (27.6)
 ≥36 42 (8.3) 57985 (8.9)
Paternal age at conception, y
 ≤25 67 (13.6) 76 700 (12.0)
 26-30 171 (34.7) 213 912 (33.4)
 31-35 149 (30.2) 211 993 (33.1)
 ≥36 106 (21.5) 138 337 (21.6)
Parental psychiatric historya
 Yes 43 (8.5) 22 854 (3.5)
 No 465 (91.5) 632 253 (96.5)
Gestational age, wk
 <28 2 (0.4) 1230 (0.2)
 28-31 9 (1.8) 4616 (0.7)
 32-36 37 (7.3) 36 556 (5.6)
 ≥37 460 (90.6) 612 705 (93.5)
Birth weight, g
 <2500 46 (9.1) 32 225 (4.9)
 2500-2999 69 (13.7) 72 735 (11.2)
 3000-3499 147 (29.2) 199 583 (30.6)
 ≥3500 242 (48.0) 346 785 (53.2)
Sex
 Boys 267 (52.6) 335 843 (51.3)
 Girls 241 (47.4) 319 249 (48.7)
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Characteristic
Valproate Exposure, No. (%)
Exposed (n = 508) Not Exposed (n = 655 107)
Congenital malformationsb
 Yes 51 (10.0) 25 568 (3.9)
 No 457 (90.0) 629 539 (96.1)
Parity
 0 239 (47.0) 283 054 (43.2)
 ≥1 269 (53.0) 372 047 (56.8)
Epilepsy (mother)
 Yes 432 (85.0) 6152 (0.9)
 No 76 (15.0) 648 955 (99.1)
a
One or both parents diagnosed with a psychiatric disorder before birth of the child (International Classification of Diseases, Eighth Revision: 
codes 290-315; International Classification of Diseases, Tenth Revision [ICD-10]: All F codes).
b
Child diagnosed with congenital malformations (ICD-10 codes Q0 to Q99, except for Q53 and Q65 [see Methods]).
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